Calando Pharmaceuticals, new Arrowhead Subsidiary, to Commercialize Therapeutic RNAi Delivery Technologies

Feb 22, 2005

NEW YORK, Feb. 22 (GenomeWeb News) - Arrowhead Research has formed a new subsidiary, Calando Pharmaceuticals, which plans to commercialize technologies for the therapeutic use of RNA interference, the Pasadena, Calif.-based company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Who Are You?

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

'Problematic'

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Republicans Take on Peer Review

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

This Week in Science

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Main menu